Estrella Immunopharma (ESLA) Competitors $1.13 -0.05 (-4.24%) As of 03:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsOwnershipSEC FilingsShort InterestTrends ESLA vs. CHRS, ADCT, VXRT, NKTX, PLX, GLSI, ACTU, DRUG, CKPT, and ADAPShould you be buying Estrella Immunopharma stock or one of its competitors? The main competitors of Estrella Immunopharma include Coherus BioSciences (CHRS), ADC Therapeutics (ADCT), Vaxart (VXRT), Nkarta (NKTX), Protalix BioTherapeutics (PLX), Greenwich LifeSciences (GLSI), Actuate Therapeutics (ACTU), Bright Minds Biosciences (DRUG), Checkpoint Therapeutics (CKPT), and Adaptimmune Therapeutics (ADAP). These companies are all part of the "pharmaceutical products" industry. Estrella Immunopharma vs. Coherus BioSciences ADC Therapeutics Vaxart Nkarta Protalix BioTherapeutics Greenwich LifeSciences Actuate Therapeutics Bright Minds Biosciences Checkpoint Therapeutics Adaptimmune Therapeutics Coherus BioSciences (NASDAQ:CHRS) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, community ranking, risk, earnings, profitability, media sentiment and valuation. Does the media refer more to CHRS or ESLA? In the previous week, Estrella Immunopharma's average media sentiment score of 1.00 beat Coherus BioSciences' score of 0.00 indicating that Estrella Immunopharma is being referred to more favorably in the news media. Company Overall Sentiment Coherus BioSciences Neutral Estrella Immunopharma Positive Which has more volatility & risk, CHRS or ESLA? Coherus BioSciences has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Estrella Immunopharma has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500. Does the MarketBeat Community prefer CHRS or ESLA? Coherus BioSciences received 447 more outperform votes than Estrella Immunopharma when rated by MarketBeat users. CompanyUnderperformOutperformCoherus BioSciencesOutperform Votes44765.26% Underperform Votes23834.74% Estrella ImmunopharmaN/AN/A Is CHRS or ESLA more profitable? Estrella Immunopharma has a net margin of 0.00% compared to Coherus BioSciences' net margin of -0.15%. Coherus BioSciences' return on equity of 0.00% beat Estrella Immunopharma's return on equity.Company Net Margins Return on Equity Return on Assets Coherus BioSciences-0.15% N/A -24.44% Estrella Immunopharma N/A -195.77%-157.28% Do analysts prefer CHRS or ESLA? Coherus BioSciences presently has a consensus price target of $5.38, indicating a potential upside of 282.29%. Given Coherus BioSciences' stronger consensus rating and higher possible upside, research analysts clearly believe Coherus BioSciences is more favorable than Estrella Immunopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coherus BioSciences 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Estrella Immunopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better valuation and earnings, CHRS or ESLA? Estrella Immunopharma has lower revenue, but higher earnings than Coherus BioSciences. Coherus BioSciences is trading at a lower price-to-earnings ratio than Estrella Immunopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoherus BioSciences$257.24M0.63-$237.89M-$0.08-17.58Estrella ImmunopharmaN/AN/A-$7.31M-$0.26-4.35 Do institutionals and insiders believe in CHRS or ESLA? 72.8% of Coherus BioSciences shares are held by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are held by institutional investors. 7.6% of Coherus BioSciences shares are held by insiders. Comparatively, 55.1% of Estrella Immunopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryCoherus BioSciences beats Estrella Immunopharma on 10 of the 15 factors compared between the two stocks. Get Estrella Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ESLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESLA vs. The Competition Export to ExcelMetricEstrella ImmunopharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$40.88M$2.99B$5.38B$9.11BDividend YieldN/A1.89%5.37%4.00%P/E Ratio-4.3545.1387.8117.51Price / SalesN/A290.151,285.9980.25Price / CashN/A189.5236.6032.90Price / Book9.423.974.944.66Net Income-$7.31M-$40.99M$117.96M$224.69M7 Day Performance5.61%2.53%2.29%3.11%1 Month Performance-2.59%-0.17%3.26%5.17%1 Year Performance-10.32%-0.85%27.03%22.24% Estrella Immunopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESLAEstrella ImmunopharmaN/A$1.13-4.2%N/A-5.6%$40.88MN/A-4.35N/ACHRSCoherus BioSciences3.8321 of 5 stars$1.47flat$5.38+265.6%-43.0%$169.36M$304.34M-18.38330ADCTADC Therapeutics2.5925 of 5 stars$1.72-8.8%$8.00+366.5%-0.3%$165.82M$70.72M-0.72310Positive NewsVXRTVaxart1.76 of 5 stars$0.72-8.8%$3.00+316.6%-0.3%$163.83M$20.14M-1.76120NKTXNkarta2.6483 of 5 stars$2.31-1.7%$15.00+549.4%-66.7%$163.01MN/A-1.23140PLXProtalix BioTherapeuticsN/A$2.20-3.1%N/A+47.0%$162.00M$45.67M-16.92200Positive NewsGLSIGreenwich LifeSciences2.1457 of 5 stars$12.26-1.0%$38.00+210.0%+41.0%$161.16MN/A-15.323ACTUActuate TherapeuticsN/A$8.08-2.7%N/AN/A$157.82MN/A0.0010Gap DownDRUGBright Minds Biosciences2.883 of 5 stars$35.41-8.9%$80.00+125.9%+1,800.2%$157.01MN/A-52.07N/ACKPTCheckpoint Therapeutics3.8085 of 5 stars$3.20+1.3%$12.00+275.0%+72.8%$156.27M$47,000.00-1.7410Positive NewsADAPAdaptimmune Therapeutics2.3592 of 5 stars$0.60-4.0%$2.79+368.3%-17.5%$152.33M$175.04M-2.71449Short Interest ↑ Related Companies and Tools Related Companies Coherus BioSciences Competitors ADC Therapeutics Competitors Vaxart Competitors Nkarta Competitors Protalix BioTherapeutics Competitors Greenwich LifeSciences Competitors Actuate Therapeutics Competitors Bright Minds Biosciences Competitors Checkpoint Therapeutics Competitors Adaptimmune Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ESLA) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Estrella Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Estrella Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
